Take Part in an FDA Approved Study for MDD with the latest Deep TMS Technology by BrainsWay About BrainsWay treatment (Deep TMS™)
BrainsWay* treatment is an innovative and revolutionary technology for the treatment of brain disorders such as MDD. The treatment is non-invasive and it stimulates the brain regions responsible for MDD using brief magnetic fields, at an amplitude similar to that used in magnetic resonance imaging (MRI) systems. The device has been cleared by the FDA for treating depression and has been studied in over 60 clinical trials around the world.
The treatment does not entail systemic side effects, which are effects deriving from medication entering the bloodstream and circulating throughout the body.
BrainsWay treatment requires only brief daily sessions over a few weeks, without indefinite or permanent medication intake.
About the Study
The study aims to demonstrate that the efficacy of the H7-Coil Deep TMS used during the treatment achieves equal or higher efficacy score as the initial FDA clearance given to H1-Coil Deep TMS in subjects suffering from Major Depressive Disorder (MDD). The treatment will take place in leading medical centers around the world and is administered by experts. It entails no surgery, hospitalization or medications, and is based on 24 brief sessions of less than 20 minutes over a period of 4 weeks and additional 2 booster treatments at the 5 and 6-week follow-up visits. During the treatment, the patient is comfortably seated in a chair, and a cushioned helmet is placed over the head generating brief magnetic fields.
Immediately after each session, patients can drive home independently and resume their daily routine. Patients can continue their current behavioral or medication treatment during the study. The study has been approved by the FDA.
Participant Criteria
Study participants should meet the following criteria: Aged 22-68, diagnosed with MDD with partial or no response to treatment and have not had any prior TMS treatment.
If you have been diagnosed with MDD, you may be eligible for the study.
Study Locations
Advanced Mental Health Care Inc. – Juno Beach, Florida, USA Contact information: Elyssa Sisko, 561-2678876, elyssasisko@gmail.com
Advanced Mental Health Care Inc. – Royal Palm Beach, Florida, USA Contact information: Elyssa Sisko, 561-2678876, elyssasisko@gmail.com
Advanced Mental Health Care Inc.- Palm Beach, Florida, USA Contact information: Elyssa Sisko, 561-333-8884, elyssasisko@gmail.com / Aron Tendler, M.D., 561-3338884, aron.tendler@gmail.com / Dr. Laura Viner – Yellowbrick1560 Sherman Avenue, Ste. 400, Evanston, IL 60201 Telephone: 847-8691500 Fax: 847-8691515
Greenbrook TMS NeuroHealth Centers – McLean, Virginia, United States
Contact information: Ms. Jessica Oleksik, 703-356-1568, joleksik@greenbrooktms.com
Principal Investigator: Geoffrey Grammer, M.D.
Center for Addiction & Mental Health (CAMH) – Toronto, Canada
Contact information: Shobha Mehta, 416-535-8501 ext 33662, Shobha.Mehta@camh.ca
Principal Investigator: Daniel Blumberger, M.D.
Medical University Of South Carolina (MUSC) – Charleston, South Carolina, USA Contact information: Contact information: Scott Henderson, 843-792-5560, henderjs@musc.edu
Kadima Neuropsychiatry – San Diego, California, USA Contact information: David Feifel, M.D., 858-412-4130, dfeifel@kadimanp.com
Soroka Hospital – Be’er Sheva, Israel
Contact information: Hadar Shalev, M.D. / Ms. Tali Gulevsky +972-8-6479180, gulevsky@post.bgu.ac.il
Comments